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A B S T R A C T
The harmonization of proteomics experiments facilitates the exchange and comparison of results. The
deﬁnition of standards and metrics ensures reliable and consistent data quality. An internal quality
control procedure was developed to assess the different steps of a proteomic analysis workﬂow and
perform a system suitability test. Themethod relies on a straightforward protocol using a simplemixture
of exogenous proteins, and the sequential addition of two sets of isotopically labeled peptides added to
reference samples. This internal quality control procedurewas applied to plasma samples to demonstrate
its easy implementation, which makes it generic for most proteomics applications.
ã 2015 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Proteomics, with its ability to generate large data sets, has
emphasized the necessity of comparing and integrating results
across laboratories and platforms. The issue has gained acuteness
as proteomics has shifted from qualitative to more quantitative
studies. At present, there is a diversity of approaches and platforms
that result in very heterogeneous data sets, whose integration
remains very challenging. A ﬁrst step toward the harmonization of
proteomics results is the deﬁnition of methods and criteria to
facilitate the systematic assessment of the analytical platform
performance and the quality of the data generated. Furthermore,
the preparation of samples using well-established procedures is
necessary. These points have been widely recognized and several
efforts have been undertaken in the past years toward the
standardization of bottom-up proteomics LC-MS/MS analyses
[1–11]. More speciﬁcally for quantitative analyses, proteomics
can actually rely on the guidelines previously established in
analytical and clinical chemistry [12,13]. While these recommen-
dations relate to a single or a limited set of analytes, the general
concepts outlined can be adopted in the context of proteomic
quantitative LC-MSmeasurements. A recent workshop, focused on
best practices for targeted analysis, has emphasized the necessity
to deﬁne the purpose of the study (ﬁt-for-purpose approach) [14].
In order to ensure the generation of reliable and consistent data
sets, a comprehensive internal qualitycontrol procedure is required. It
has to include the assessment of the sample preparation and the
qualiﬁcation of the instrument, which are combined in a validated
analytical method. This provides a system suitability test, required
prior to the analysis of actual samples [15]. The sample preparation
method, which covers the sample handling, digestion, extraction and
dilution,has tomatchtheanalyticalquestion, thetypeofsamplestobe
analyzed, and has to be reproducible across series of samples. The
instrument and its associated operation method need to be speciﬁc
and evaluated on test samples to assess the fulﬁllment of predeﬁned
requirements, in termsofanalytical sensitivity (limitsofdetectionand
quantiﬁcation), selectivity, precision (determined from replicated
experiments), accuracy (basedon theanalysisof a referencematerial),
andlastlyrobustness.Boththesamplepreparationandtheinstrument
methodneed tobe evaluated,ﬁrst independentlyandultimately in an
integrated manner. A robust and validated protocol represents the
basis for an internal quality control and its routine implementation. It
allows the assessment of (i) the instrument performance, (ii) the
sample preparation performance, and (iii) the system suitability.
A quantitative proteomics workﬂow needs to be speciﬁc,
somehow addressing a well-deﬁned analytical question. At
present, most proteomics experiments are generic; nevertheless
some level of systematic quality control is imperatively required. In
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an attempt to apprehend all the elements of a bottom-up LC-MS/
MS proteomic workﬂow and monitor the different stages of the
process, a simple protocol was designed. It allows the system
suitability for routine proteomic analyses to be qualiﬁed while
overcoming the rigidity of a full method validation. Rigorous
quality controls remain required for systematic quantitative
studies (e.g., preclinical), whereas relaxed constraints are applica-
ble for initial screening experiments [14]. The protocol that was
recently proposed to routinely assess the uniformity of proteomics
analyses addresses this point [16]. It evaluates sample preparation
and instrument performances concomitantly through the addition
of isotopic variants of internal standards (peptides isotopically
labeled with different motifs) at several stages of the workﬂow,
corresponding to two peptides of each protein from the standard
proteinmixture. The analysis of these peptides in buffer enables to
test the suitability of the LC–MS platforms, using acceptance/
rejection metrics that were established based on long-term data
collection. The systematic implementation of the protocol allows
to monitor LC–MS performance overtime and to detect possible
drifts or dysfunctions. It can also be employed to compare
sensitivity levels of different platforms or analytical methods.
In an attempt to expand its applicability to clinical samples, the
simple quality control procedure based on the sequential addition
of multiple isotopically labeled peptides was tested on plasma
samples. In this account, the standard protein mixture designed
was spiked into several plasma samples, and the reproducibility of
the overall workﬂow was assessed using control charts, which
allows to deﬁne acceptance criteria. The quality control procedure
is easily applicable in individual laboratories, and has shown a high
level of reproducibility and robustness when applied to plasma
samples, used as reference materials.
2. Material and method
2.1. Chemicals and reagents
Dithiothreitol, formic acid, iodoacetamide, Tris–HCl (Trizma
hydrochloride), and urea were purchased from Sigma–Aldrich (St.
Louis, MO, USA). Sequencing grade modiﬁed trypsin was obtained
from Promega (Madison, WI, USA). All solvents used were HPLC
grade and purchased from Sigma–Aldrich.
2.1.1. Standard materials
The mixtures of three proteins and stable-isotope labeled (SIL)
peptides were prepared as previously explained [16] (Supplemen-
tary Table).
2.1.2. Sample preparation
The unfolded standard protein mixture was either spiked in
plasma samples or underwent the sample preparation procedure
in buffer. Six plasma samples from deidentiﬁed human specimens
were provided by Integrated BioBank of Luxembourg (IBBL) and
treated as “not human subjects research” materials. Each plasma
sample was individually mixed with the standard protein mixture
(15mL, volume corresponding to 7.5mg of each protein) at a ﬁnal
concentration of 300ng/mL. The reduction was performed with
20mM dithiothreitol (5mM ﬁnal concentration) by incubation at
37 C for 30min. Then, the protein mixtures were alkylated with
75mM iodoacetamide (15mM ﬁnal concentration) for 30min at
25 C in the dark before the addition of a ﬁrst set of isotopically
labeled peptides (HA peptides) at a ﬁnal nominal concentration of
50 [75_TD$DIFF]fmol/mL. A solution of 25mM Tris–HCl was used to dilute urea
to 1M and sequencing grade modiﬁed trypsin was added to a ﬁnal
enzyme:substrate ratio of 1:20. After an incubation of 4h at 37 C,
peptides were cleaned on Sep-Pak tC18 cartridges (Waters,
Milford, MA, USA) and eluted with 50% acetonitrile. The samples
were lyophilized on a vacuum centrifuge and resolubilized in 0.1%
formic acid. Prior to LC-MS/MS analysis, the mixtures were
supplemented with a second [76_TD$DIFF]set of isotopically labeled peptides
(HB peptides) at a ﬁnal nominal concentration of 50 fmol/mL. [77_TD$DIFF] n
addition to the standardmaterials, amixture of isotopically labeled
peptides corresponding to 42 peptides from plasma was added
before LC-MS/MS analysis on the quadrupole orbitrap instrument
at [78_TD$DIFF]a concentration close to that of their endogenous counterpart.
2.2. Liquid chromatography and mass spectrometry
2.2.1. LC separation
Analyseswere carried out on aUltimate 3000 RSLC nano system
(Thermo Scientiﬁc). A trap column Acclaim PepMap 2 cm75mm
i.d., C18, 3mm, 100 A and an analytical column Acclaim PepMap
RSLC 15 cm [79_TD$DIFF] 5mm i.d., C18, 2mm,100 A (Thermo Scientiﬁc) were
used. The samples were loaded into the trap column at 5mL/min
with [80_TD$DIFF]an aqueous solution containing 0.05% triﬂuoroacetic acid and
1% (v/v) HPLC grade acetonitrile. After three minutes loading, the
trapping column was put on-line with the analytical column. The
peptides were eluted by applying a mixture of solvent A/B. Solvent
A was HPLC grade water with 0.1% (v/v) formic acid, and solvent B
was HPLC grade acetonitrile with 0.1% (v/v) formic acid. Separation
was performed using a linear gradient of 2–35% solvent B at 300nL/
min either over 33min for analyses performed on the triple
quadrupole instrument (SRM) or over 66min for analyses carried
out on the quadrupole orbitrap instrument (PRM). One microliter
of each sample was injected.
2.2.2. Analyses on triple quadrupole instrument
Selected reactionmonitoring analyses were carried out on a TSQ
Vantage extendedmass range triple quadrupolemass spectrometer
(Thermo Scientiﬁc, San Jose, CA, USA). A dynamic nano-electrospray
source was used with uncoated SilicaTips, 12 cm length, 360mm
outer diameter, 20mm inner diameter, 10mm tip inner diameter.
Ionization was obtained by using 1200V of liquid junction voltage
and 250 C for the capillary temperature. The selectivity for both
Q1andQ3wasset to0.7Da.ThecollisiongaspressureinQ2wassetat
1.5mTorrargon.The time-scheduledSRMmethodtargeted6 triplets
of isotopically labeled peptides/endogenous peptides in  [81_TD$DIFF]6min
retention time windows by monitoring ﬁve transitions for each
peptide within a cycle time of 2.5 s.
2.2.3. Analyses on quadrupole orbitrap instrument
Parallel reaction monitoring analyses were performed on a Q-
Exactive HF mass spectrometer (Thermo Scientiﬁc, Bremen,
Germany). The nano-electrospray source was identical to the one
used for analyses performed on the triple quadrupole mass
spectrometer. For ionization, 1500V of liquid junction voltage was
used. The acquisitionmethod included a full scan event (mass range
of 300–1500m/z), using a resolution of 60,000 (atm/z 200), a target
automatic gain control value of 1e6, and a maximum ﬁll time of
100ms. The second event consisted in a PRM scan event operating
with a 2-Th isolationwindow, a resolution of 30,000 (atm/z 200), a
target AGC value of 1e6, a maximum ﬁll time of 120ms, and a
normalized collision energy set at 25. The time-scheduled method
targeted the six triplets of standard peptides [82_TD$DIFF](two labeled and one
unlabeled) derived from proteins of the standard [83_TD$DIFF]mixture, and
42pairsofendogenous/isotopically labeledpeptidesfromplasmain
 [84_TD$DIFF]2min chromatographicmonitoringwindows. Some experiments
were replicated on a quadrupole orbitrap plus instrument.
3. Data processing
Data analysiswas performed using Skyline (Vers. 2.6, University
of Washington). The area under the curve (AUC) of each target
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transition was calculated for all the isotopic variants of the
peptides of the reference mixture. The AUC [85_TD$DIFF]of each individual
transition were summed together to quantify each peptide.
4. Results and discussion
4.1. [86_TD$DIFF] esign of a simple quality control procedure
Ideally, a quality control protocol intended to assess the
performance of a proteomic workﬂow should use isotopically
labeled recombinant proteins, added at the beginning of the
experiment. Such standards, corresponding to the endogenous
targets in the study, yield an estimation of the digestion efﬁciency
of the proteins of interest, provided they reﬂect the native proteins
(e.g., modiﬁcations). Although very useful, and the ultimate choice
for clinical studies, the approach remains difﬁcult to apply
generically. A quality control procedure including a mixture of
exogenous proteins and the multiple-addition of internal stand-
ards, used as surrogate peptides for the standard proteins, enables
to determine the recovery and monitor the reproducibility of the
different stages of the process (Fig. 1A, Supplementary Table). The
standard peptides added at different stages of the workﬂow
highlight anomalies. Furthermore, for routine analysis of clinical
samples, an internal standard that can be spiked into a reference
sample (i.e., plasma, called reference material) representative of
the sample type used in the study constitutes a generic solution for
proper evaluation of the workﬂow. The sequential addition of
isotopically labeled variants of the peptides provides a better read-
out and a detailed view of data quality, indicating possible
deviations.
The quality control procedure developed is simple and
straightforward, and allows a routine system suitability test prior
to the analysis of the actual samples. It monitors the performance
of sample preparation and instrument while added in control
samples. For its ﬁrst iteration, to demonstrate proof-of-principle, a
set of three exogenous proteins was selected (i.e., non-human,
called standard protein mixture). The double addition of internal
standards allows the detection of inconsistencies in the individual
stages of theworkﬂow (i.e., digestion, desalting, or LC-MS analysis)
(Fig.1A). A ﬁrst set of isotopically labeled internal standards (called
peptides HA; corresponding to the peptides derived from exoge-
nous proteins) was added prior to the digestion, and the second
one (called peptides HB; with a different isotopic incorporation)
immediately before LC–MS analysis. The amounts of spiked
synthetic peptides were calibrated to be equimolar, i.e., [87_TD$DIFF]to show
a triplet of signals with the same intensitywhen analyzed byMS or
MS/MS [16]. The quality control procedure was applied to monitor
the overall workﬂow, as depicted on the control charts, and thus
represents the initial baseline used to deﬁne acceptance criteria.
Regarding the sample preparation, a recovery within 85–115%
range was considered as acceptable in buffer solution [17], and
outliers were detected by the Grubb’s test (Fig. 1B). The status of
the LC-MS/MS platform was monitored through chromatography
metrics related to the peak area and peak shape (full width at half
maximum, FWHM), whose thresholds were set at two and three
standard deviations around the mean values determined over an
[(Fig._1)TD$FIG]
Fig. 1. Quality control procedure based on the sequential addition of isotopically labeled peptides. (A) Diagram of the analytical procedure. (B) Control chart of the sample
preparation efﬁciency. The acceptance criteria were set at 15% around the expected value of one. (C), (D), (E) Monitoring of the performance of the LC-MS/MS platform. (C
and D) The acceptance criteria of the peak area and full width at half maximum were set at two and three standard deviations around the mean value corresponding at a
warning and an action threshold, respectively. (E) The tolerance on the elution time was set at  [72_TD$DIFF]1min around the mean value. Yellow points corresponds to outliers. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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extended period of time (Fig. 1C and D). Lastly, for the
chromatographic elution [88_TD$DIFF]time, an acceptance window of two
minutes around the mean value of each peptide was established
(Fig. 1E).
In the present study, the multiple internal standards approach
was applied to clinical samples. The standard protein mixture was
added to plasma samples, which were then processed with the
simple protocol described above. Prior to perform LC-MS/MS
analysis, the buffer solution of standard peptides was analyzed by
LC-MS/MS to check the suitability of the platform, ensuring that all
acceptance criteria were fulﬁlled. Then, plasma samples were
analyzed and the standard peptides were quantiﬁed to estimate
the overall efﬁciency of the process. Concomitantly, the standard
protein mixture was processed in buffer using the same protocol,
including the desalting step, to assess the efﬁciency of this
operation. The acceptance thresholds were established based on [89_TD$DIFF]a
long-term reproducibility study of the process without the
desalting step included.
4.2. [90_TD$DIFF]Application to plasma samples
The quality control procedure was applied to plasma samples.
The experiment was replicated ten times using one representative
plasma sample, in which the standard protein mixture was added
at the beginning of the preparation. The digests, and spiked
peptides obtained through the full analytical procedure were
analyzed by LC–SRM. The SRM traces of each of the targeted
standard isotopologous peptides (six triplets in total) were
extracted to assess the recovery of the process. More speciﬁcally,
the consistency of the protein digestion in this more complex
medium was assessed by comparing the signals of the peptides
derived from the standard proteinmixture (L) with those of the SIL
peptides added prior to digestion (HA). As indicated in Fig. 2A, a
recovery within 85–115% was systematically obtained for ﬁve
peptides (CV below 11%), while it slightly, but reproducibly,
dropped below the acceptance criteria (82%) for one peptide
(GGYFDSIGIIR). This conﬁrmed the robustness of the sample
preparation protocol, and more speciﬁcally the digestion step,
which was only marginally affected by the increase in complexity
due to the plasma matrix. The estimation of the recovery of the
overall process is reﬂected by the comparison of the signal of the L
peptideswith the signal of the SIL standard peptides added prior to
LC–MS analysis (HB). More speciﬁcally, the L/HB peptides signal
ratios were lower than the acceptance threshold (Fig. 2B),
indicating a signiﬁcantly higher abundance for peptides added
prior to the LC–MS analysis as compared to the exogenous peptides
derived from the spiked proteinmixture. As the signal ratios of the
L/HA peptides were in line with acceptance criteria, the inconsis-
tency of the signal ratios of the L/HB peptides was attributed to
losses occurring during the last part of the process (i.e., handling
and desalting). To further investigate the reason of this deviation
and identify the critical step, the procedure was applied to plasma
samples and buffer solutions. The quality control performed on the
sample in buffer with the desalting step (green on the charts)
demonstrated higher efﬁciency, reﬂected by L/HB ratios close to
one. The desalting step in plasma samples showed one abnormality
for the peptideGVLHAVK that suffered fromavery lowand variable
recovery due to high hydrophilicity, and poor retention on reversed
phase [91_TD$DIFF]SPE cartridge. The ﬁve other standard peptides showed a
reproducible recovery over the entire procedure (CV below 15%,
Fig. 2B). The double addition of internal standards combined with
LC-MS/MS analysis allows to assess the recovery and more
importantly the consistency of the full preparation. It immediately
pinpoints to discrepancies, as illustrated with the peptide
GVLHAVK. However, the application of the quality control
procedure in plasma demonstrated the necessity to reﬁne the
acceptance thresholds according to the matrix used in the study.
The high reproducibility obtained with one plasma sample is not
sufﬁcient and an extended set of plasma samples is required to
establish a baseline for a large pre-clinical study.
4.3. [92_TD$DIFF]Quality control and robustness of the method
The robustness of the procedure was further assessed by
replicating three times the experiment on ﬁve plasma samples over
one month. Compared with the preliminary experiments described
above, theprocedurewasonlyslightlymodiﬁedto includea [93_TD$DIFF]reversed
phase SPE cartridge of higher capacity at the desalting step level. In
our hand, reproducible results were obtained as illustrated in Fig. 3.
The recovery determined for the digestion step (assessed by L/HA
ratio, Fig. 3A) as well as for the overall procedure (assessed by L/HB
ratio, Fig. 3B), was characterized by a low coefﬁcient of variation,
whichwas typically below 15% for each plasma sample analyzed by
SRMonthetriplequadrupoleandbyPRMonthequadrupoleorbitrap
instrument. The variation in background, inherent to samples of
distinct individuals, thus did not affect the procedure efﬁciency. The
recovery of the desalting stepwasmoderately enhanced, beneﬁting
from the optimization of the solid phase extraction cartridge
capacity, resulting ina lowervariability for thepeptideGVLHAVK(CV
of 15%).
Furthermore, during PRM analyses on the quadrupole orbitrap
instruments a series of 42 endogenous plasma peptides were
concomitantlymonitoredwith their isotopically labeled counterparts
also spiked in the samples. Thequantitative results of the endogenous
[(Fig._2)TD$FIG]
Fig. 2. Reproducibility of the double addition of internal standard in plasma sample. The sample preparation was replicated ten times over two weeks for two different
conditions (inplasma samples and in buffer). The six resulting peptideswere analyzed by LC-SRMon a triple quadrupolemass spectrometer. The numbers 1 [73_TD$DIFF]to 6 correspond to
peptides GVLHAVK, GVIFYESHGK, NVNDVIAPAFVK, NTVISVFGASGDLAK, VVGLSTLPEIYEK, and GGYFDSIGIIR, respectively. For each standard peptide the area ratios of the
unlabeled form “L” over its isotopically labeled counterpart “HA” (added prior to the digestion) and “HB” (added prior to LC-MS/MS analysis) are presented in panel (A) and (B),
respectively.
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peptides are presented in Supplementary material. They exhibited
high reproducibility within each plasma sample while reﬂecting the
variable inter-sample abundance. This is illustrated by the results
obtained for three selected peptides presented in Fig. 4. All these
peptides were measured with a low CV (typically below 10%) in
replicated analyses of each plasma sample while two of them
exhibited a variable abundance across the [94_TD$DIFF]samples. Indeed, peptide
LGNQEPGGQTALK (corresponding to alpha-2-antiplasmin) was re-
producibly and consistently measured in a similar amount in all [95_TD$DIFF]
plasmadigests.However,peptidesALQDQLVLVAAK(correspondingto
angiotensinogen) and NPANPVQR (corresponding to haptoglobin)
were present in different amounts in the various plasma samples. For
instance, peptide ALQDQLVLVAAK was three to ﬁve times more
concentrated in plasma #3 compared to the other samples whereas
peptide NPANPVQR was present in a very low concentration in the
digest fromplasma#2 i.e., 40–100 times less concentrated than in the
other samples.
These results demonstrate the pertinence of the quality control
when applied to plasma samples, as it is able to highlight
abnormalities in the level of the endogenous peptides of interest.
The standards spiked in biological samples allow the reproduc-
ibility and the performance of both sample preparation and
analyses on LC–MS platforms to be monitored, as required to
ensure reliability of the results.
5. Conclusion
The routine use of LC–MS based proteomics methods in
biomedical studies and the necessity to generate comparable results
have emphasized the need of standardization of the analytical
process. A simplequalitycontrol procedurewasproposed to address
this requirement; it is basedon the combinationof a straightforward
protocol and the sequential addition of two sets of six standard
peptides with characteristic isotopic patterns. The amino acid
sequence of these peptides is identical to surrogates peptides
generated from the exogenous proteins added into the sample. The
aim of this procedure is to perform a system suitability test, and to
monitor the performance of both the sample handling and the LC–
MS platforms involved in the analytical process. In proteomics
experiments, in which the samples processed range from fairly to
highly complex, a quality control obtained by spiking an internal
standard into the sample at the beginning of the process is required.
The exogenous protein mixture was spiked in highly complex
samples and underwent the sample preparation and analyses using
standard LC–MS methods. The procedure applied to plasma
referencematerial demonstratedhigh reproducibility. Furthermore,
inadditiontothestandardpeptidesmonitored, theanalysis included
endogenous peptides from plasma digest.
In a pre-validation study performed on test samples, the
boundaries of the assays were assessed, and were used to deﬁne
metrics and estimate acceptance criteria. They represent a basis for
large studies, performed to validate the acceptance/rejection
thresholds. According to common practice, the mean and standard
deviation (STD) of a set of values collected over longer periods
allow the deﬁnition of the warning (2STD) and the action
thresholds (3STD), respectively. Furthermore, the procedure
guides system suitability checks; according to previous recom-
mendations [18] an internal quality control is required every
twenty samples for routine analyses, and every ﬁve or two samples
for [96_TD$DIFF]more complex processes. Considering the complexity of clinical
[(Fig._3)TD$FIG]
Fig. 3. Robustness of the quality control procedure applied to plasma samples. The sample preparation was performed on ﬁve distinct plasma samples and replicated three
times over one month. The six resulting peptides were analyzed by LC–SRM on a triple quadrupole mass spectrometer. The numbers 1 [73_TD$DIFF]to 6 correspond to peptides GVLHAVK,
GVIFYESHGK, NVNDVIAPAFVK, NTVISVFGASGDLAK, VVGLSTLPEIYEK, and GGYFDSIGIIR, respectively. For each standard peptide the area ratios of the unlabeled form “L” over
its isotopically labeled counterpart “HA” (added prior to the digestion) and “HB” (added prior to LC-MS/MS analysis) are presented in panel (A) and (B), respectively.
[(Fig._4)TD$FIG]
Fig. 4. Reproducibility of the measurement of endogenous peptides from plasma samples mesured concomitantly with the internal standard peptides. The sample
preparation was performed on ﬁve distinct plasma samples and replicated three times over one month. The resulting peptides were analyzed by LC–PRM on quadrupole
orbitrap instruments. The area ratios of three endogenous peptides over their isotopically labeled counterparts added prior to LC-MS/MS analysis are presented on each chart.
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proteomics samples, the latest scenario is the most likely to
happen.
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